| Preclinical Research | Clinical Research | ||||
|---|---|---|---|---|---|
| Medicinal Discovery | Optimization of Drug Candidates | Preparations for Clinical Studies* | Clinical Phase I** | Clinical Phase II*** | Phase III |
rugocrixan– Myocardial infarction (inflammation) |
|||||
rugocrixan– Ovarian cancer |
|||||
fosrugocrixan– First in human (healthy subjects)) |
|||||
The transparent fields illustrate ongoing funded projects
* Toxicologi & Production
** Safety, Tolerability & Drug Properties
*** Safety, Tolerability, Pharmakologi, Clinical Effect & Dosing
Since its foundation, Kancera has established world class preclinical research capabilities and demonstrated the ability to advance candidate drugs into clinical development. Kancera’s pipeline now consists of two candidate drugs that are being studied in three clinical trials:
FRACTAL – a phase IIa study of rugocrixan in STEMI patients undergoing PCI. The study is completed and the company reported positive top line results in December 2023. The company is now workning on the preparations for a next clinical study, a phase IIb study in the same patient population (FRACTIVE).
KANDOVA – an ongoing combined phase Ib/IIa study of rugocrixan in ovarian cancer patients with relapse from carboplatin therapy. The study is completed and the company reported positive top line results in June 2025.
KAND145 First-in-human – a phase I study of Kancera’s second generation CX3CR1 antagonist in healthy subjects. The study is completed and the company reported positive top line results in May 2024.
FRACTAL – rugocrixan in myocardial infarction
FRACTAL is a phase IIa study in ST-elevated myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI). The study, a randomized, two-armed, placebo-controlled, double blinded, multi-center study, has been completed and positive top line results were presented in December 2023.
The company is now workning on the preparations for a next clinical study, a phase IIb study in the same patient population (FRACTIVE).
KANDOVA – rugocrixan in ovarian cancer
KANDOVA is a combined phase Ib/IIa study in ovarian cancer patients with relapse from carboplatin therapy. The study is an open label, multi-center, intra-patient dose escalation study (part one) with an expansion cohort (part two) of rugocrixan in combination with carboplatin. The study, conducted in collaboration with NSGO-CTU at five university hospitals in Sweden, Denmark and Norway, is completed and the company reported positive top line results in June 2025.
KAND145 First-in-human – phase I study in healthy subjects
The study is a randomized, placebo-controlled, multi-center, first in human study of KAND145 (fosrugocrixan) in healthy subjects to evaluate safety, tolerability, pharmacokinetics, food effect and interaction with other drugs. The study is completed and the company reported positive top line results in May 2024.
Preclinical development
Through its function as a regulator of specific immune cells, the fractalkine axis plays an important role in several acute and chronic inflammatory diseases, autoimmune disease as well as complications in connection with transplantations. Kancera is evaluating opportunities for treatment of new inflammatory diseases with high medical need of more effective treatments.